Hepatic Safety of Statin Use in Neurology Inpatients

Recruiting now

Conditions studied: Statin Adverse Reaction

In brief

This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.

Key facts

Study ID

NCT06592196

Run by

Shanghai Yueyang Integrated Medicine Hospital

People needed

2000

Starts

2024-08-10

Expected to finish

2024-12-10

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients hospitalized in the Department of Neurology of Yueyang Hospital from June 2020 to February 2023.
• Age ≥18 and ≤85 years old, both sexes.
• Meet the diagnostic criteria of cerebrovascular disease (L1-8B0), headache disease (L1-8A8) and dizziness and vertigo (MB48) in ICD-11.

You may not qualify if…

• Incomplete medical history.
• 1 days ≤ patients with < 7 days of prior statin use.
• Patients with malignant tumors (ICD-11 code L1-2A0, L1-2A2, L1-2B5, L1-2E6 diseases) and hematological diseases (ICD-11 code L1-3A0, L1-3B1, L1-3B8 diseases).

Where it is running

• Shanghai Yueyang Integrated Medicine Hospital — Shanghai, Shanghai Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.